Protein Engineering, Vol. 14, No. 10, 815-823,
October 2001
© 2001 Oxford University Press
Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies
Institut für Molekularbiologie und Tumorforschung, Philipps-Universität Marburg, Emil-Mannkopff-Strasse 2, 35033 Marburg, Germany
Bispecific single-chain diabodies (scDb) consist of the variable heavy and light chain domains of two antibodies connected by three linkers. The structure of an scDb in the VH–VL orientation is VHA–linkerA–VLB–linkerM–VHB–linkerB–VLA, with linkers A and B routinely chosen to be 5–6 residues and linker M 15–20 residues. Here, we applied display of scDb on filamentous phage to analyse the composition of optimal linker sequences. The three linkers were randomized in length and sequence using degenerated triplets coding for only six hydrophilic or aliphatic amino acids (Thr, Ser, Asp, Asn, Gly, Ala). Antigen-binding clones were then isolated by one to two rounds of selection on the two different antigens recognized by the bispecific scDb. Using an scDb directed against carcinoembryonic antigen (CEA) and ß-galactosidase (Gal), we found that monomeric scDb had a preferred length of 15 or more amino acid residues for the middle linker M and of 3–6 residues for the linkers A and B. No obvious bias towards a preferred linker sequence was observed. Reduction of the middle linker below 13 residues led to the formation of dimeric scDb, which most likely results from interchain pairing between all the VH and VL domains. Dimeric scDb were also formed by fragments possessing a long linker M and linkers A and B of 0 or 1 residue. We assume that these dimeric scDb are formed by intrachain pairing of the central variable domains and interchain pairing of the flanking variable domains. Thus, the latter molecules represent a novel format of bispecific and tetravalent molecules. The described strategy allows for the isolation of both optimized and minimal linker sequences for the assembly of monomeric or dimeric single-chain diabodies.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. C. Peterson, E. M. Laurenzana, W. T. Atchley, H. P. Hendrickson, and S. M. Owens Development and Preclinical Testing of a High-Affinity Single-Chain Antibody against (+)-Methamphetamine J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 124 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Muller, A. Karle, B. Meissburger, I. Hofig, R. Stork, and R. E. Kontermann Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin J. Biol. Chem., April 27, 2007; 282(17): 12650 - 12660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Le Gall, U. Reusch, M. Little, and S. M. Kipriyanov Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody Protein Eng. Des. Sel., April 1, 2004; 17(4): 357 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Pleass, S. A. Ogun, D. H. McGuinness, J. G. J. van de Winkel, A. A. Holder, and J. M. Woof Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection Blood, December 15, 2003; 102(13): 4424 - 4430. [Abstract] [Full Text] [PDF]
|
|